The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,766.00
Bid: 2,113.00
Ask: 1,678.50
Change: 5.00 (0.28%)
Spread: -434.50 (-20.563%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1,761.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Star fund manager exits can prove a blow to small caps

Fri, 25th Oct 2013 16:56

* Small caps seen vulnerable after Woodford leaves Invesco

* Could take thousands of days to liquidate - Markit

* Analysts urge caution in tracking 'star' managers

By Tricia Wright

LONDON, Oct 25 (Reuters) - Small companies favoured by topfund manager Neil Woodford risk steep sell-offs in the run-up tohis departure from Invesco, underscoring the dangers for retailinvestors who track the views of such "stars".

Invesco Perpetual's announcement earlier this month thatWoodford would leave in April - the latest high-profile fundindustry departure - sparked price falls in both blue-chip andsmall-cap stocks that he holds.

Analysts say the sell-off is likely to accelerate as hisdeparture date approaches, with most impact on small companiesbecause his holdings represent a relatively large part of theirmarket cap and investors won't want to be left holding sharesthat have lost their famous champion.

Outflows are likely simply because of Woodford's status,even if the new manager shares his world view. There wereoutflows from Schroders earlier this year when equityfund manager Richard Buxton quit, while the departure ofmanagers such as Roger Guy from Gartmore in 2011 was quicklyfollowed by the loss of hefty amounts of client cash.

Such outflows may force a fund to sell some of its holdingsto pay back the investors.

Woodford "might have big positions in the likes ofGlaxoSmithKline and companies like that - but they'rebig companies so they can absorb some of that impact (of apotential sale of holdings) much more easily," said AdrianLowcock, a senior manager at investment management firmHargreaves Lansdown.

"The issue... is really in the smaller caps, because hestill has some quite strong positions in some small andmid-sized companies... If it became known that (the fund) wasforced to sell them (to repay investors) that could create hugevolatility."

Invesco is the largest or second largest shareholder in 22of the 25 small cap companies Woodford holds, analysts at Markitsaid in a note. Daily trade in such shares is often numbered inthe thousands rather than the millions traded in larger firms.

Markit said those small cap holdings would take "hundreds ifnot thousands" of trading days to completely liquidate. Thissuggests that if the shares are sold quickly, the price fallwould be significant and much more pronounced than any losses inthe share price of the blue-chip companies.

This would be likely to hit retail investors, who, in theuncertain environment of the financial crisis, have sought theperceived security of following successful managers likeWoodford. He kept away from the dotcom bubble in the late 1990sand avoided banks before Lehman Brothers' collapse.

"We do get people phoning in and saying 'I notice so and sohas exited their position entirely - what should we do? What'sthe view? What's the reason for them doing that sort of thing?'"Sam Petts, partner at stockbroker Killik & Co, said.

With funds' holdings publicised and widely available, manyinvestors use them as a guide for their own decisions even ifthey do not buy into the fund directly.

"There's one client who I speak to regularly... he willscour around and specifically look for companies where aparticular hedge fund has a significant holding and that hedgefund has a good track record," Yusuf Heusen, trader at IG, said.

Analysts stressed the need not to become fixated by a fundmanager's reputation.

"Mostly people base their investment decisions on aperception of what feels like a good investment. This perceptionis often quite a different thing from a good investment itself,"said Greg Davies, managing director and head of behavioural andquantitative finance at Barclays.

"No matter how good a star manager is, by the time they'vegot this cult status, regardless of how well deserved,... cultstatus by its very nature is an excessive devotion to a name."

For further stories on the implications of Woodford'sdeparture:

More News
7 May 2024 09:51

LONDON BROKER RATINGS: AstraZeneca target raised; Antofagasta lowered

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Friday:

Read more
2 May 2024 19:57

GSK knew about Zantac cancer risk, attorneys tell jury in first trial

May 2 (Reuters) - U.S. attorneys for a woman who claims her colon cancer was caused by the now discontinued heartburn drug Zantac on Thursday told a jury in Chicago that pharmaceutical companies GSK and Boehringer Ingelheim knew the product could cause cancer if it was not handled properly but failed to warn the public.

Read more
2 May 2024 09:48

LONDON BROKER RATINGS: Deutsche Bank likes TP ICAP but says sell CMC

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and Wednesday:

Read more
1 May 2024 19:39

Bird flu testing shows more dairy products are safe, US FDA says

CHICAGO, May 1 (Reuters) - Preliminary results of tests on additional dairy products show that pasteurization inactivates the bird flu virus, the U.S. Food and Drug Administration said on Wednesday.

Read more
1 May 2024 17:31

UK's FTSE 100 slips ahead of Fed outcome, energy stocks weigh

FTSE 100 down 0.3%, FTSE 250 off 0.2%

*

Read more
1 May 2024 16:56

LONDON MARKET CLOSE: FTSE 100 down ahead of US interest rate decision

(Alliance News) - Stock prices in London closed mostly in the red on Wednesday, as investors eye the latest interest rate decision from the US Federal Reserve this evening.

Read more
1 May 2024 16:42

London close: Stocks fall ahead of US Fed decision

(Sharecast News) - London markets closed lower on Wednesday, as investors digested the latest UK manufacturing data and anticipated an impending policy announcement from the US Federal Reserve.

Read more
1 May 2024 11:55

LONDON MARKET MIDDAY: FTSE 100 treads water as Fed takes centre-stage

(Alliance News) - London's FTSE 100 traded off session highs heading into Wednesday afternoon, as some pre-Federal Reserve decision nerves kicked in.

Read more
1 May 2024 10:54

GSK raises profit outlook on strong vaccine, HIV drug sales

FY profit forecast raised to 8-10%

*

Read more
1 May 2024 08:57

LONDON MARKET OPEN: FTSE 100 shakes off New York slump before Fed

(Alliance News) - Stock prices in London opened mixed on Wednesday, with the FTSE 100 brushing off some pre-Federal Reserve decision trepidation to record an early rise, while the dollar climbed on the expectation that Jerome Powell will sound hawkish in his press conference later.

Read more
1 May 2024 08:50

TOP NEWS: GSK expects momentum to continue after strong first quarter

(Alliance News) - GSK PLC on Wednesday raised its annual earnings forecast, and said it expects sales growth at the top-end of guidance, after a "strong" start to the year.

Read more
1 May 2024 07:46

LONDON BRIEFING: GSK ups outlook; Next first-quarter beats forecast

(Alliance News) - Equities in London are called to open flat on Wednesday, ahead of the latest Federal Reserve interest rate decision, while a host of financial markets in mainland Europe and beyond are closed for public holidays.

Read more
1 May 2024 07:36

GSK lifts annual guidance on strong virus treatment sales

(Sharecast News) - UK pharmaceutical giant GSK lifted annual profits guidance on Wednesday, as it pinned its hopes on demand for its respiratory virus and shingles treatments.

Read more
30 Apr 2024 23:46

First trial over Zantac cancer claims set to begin in Chicago

April 30 (Reuters) - The first trial over claims that blockbuster heartburn drug Zantac, once sold by GSK and other companies, causes cancer is set to begin this week in Chicago.

Read more
30 Apr 2024 22:39

First trial over Zantac cancer claims set to begin in Chicago

April 30 (Reuters) - The first trial over claims that blockbuster heartburn drug Zantac, once sold by GSK and other companies, causes cancer is set to begin this week in Chicago.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.